journal
Journals American Journal of Cardiovasc...

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions

https://read.qxmd.com/read/39017985/sodium-glucose-cotransporter-2-inhibitors-elevating-standards-in-cardiovascular-secondary-prevention
#1
LETTER
Antonio Greco
No abstract text is available yet for this article.
July 17, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38976171/the-use-of-drugs-that-should-be-avoided-or-used-with-caution-in-patients-hospitalized-for-acute-decompensated-heart-failure
#2
JOURNAL ARTICLE
Marwan Sheikh-Taha
BACKGROUND: Heart failure (HF) is a pervasive global health concern, with acute decompensated heart failure (ADHF) contributing significantly to morbidity and mortality. Medications used in patients with HF may exacerbate HF or prolong the QT interval, posing additional risks. OBJECTIVE: The objective is to assess the prevalence and utilization patterns of medications known to cause or exacerbate HF and prolong the QT interval among patients with ADHF. Understanding these patterns is crucial for optimizing patient care and minimizing potential risks...
July 8, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38969953/empagliflozin-effects-in-patients-with-st-elevation-myocardial-infarction-undergoing-primary-pci-the-emi-stemi-randomized-clinical-trial
#3
JOURNAL ARTICLE
Elnaz Khani, Naser Aslanabadi, Kazem Mehravani, Haleh Rezaei, Hoda Afsharirad, Taher Entezari-Maleki
INTRODUCTION: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves cardiovascular outcomes in heart failure patients, but data regarding the efficacy of empagliflozin in the setting of acute myocardial infarction (AMI) is still unclear. The current study aimed to evaluate whether treatment with empagliflozin before primary percutaneous coronary intervention (PCI) improves parameters associated with patients' outcomes. METHODS: We randomly assigned 101 non-diabetic and non-heart failure patients with ST-elevation myocardial infarction (STEMI) who underwent primary PCI to receive either empagliflozin (10 mg before PCI and once daily for 40 days) or placebo, in addition to the standard treatment...
July 5, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38963527/impact-of-sglt2-inhibitors-on-atrial-fibrillation-recurrence-after-catheter-ablation-in-type-2-diabetes-mellitus-a-meta-analysis-of-reconstructed-kaplan-meier-curves-with-trial-sequential-analysis
#4
JOURNAL ARTICLE
Youssef Soliman, Mohamed Abuelazm, Basma Ehab Amer, Mishaal Hukamdad, Mohamed Hatem Ellabban, Nada Ibrahim Hendi, Adel Mouffokes, Basel AbdelAzeem, Hatem Hassaballa
PURPOSE: The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in managing cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) is evolving. This meta-analysis seeks to explore the influence of SGLT2i on the recurrence of atrial fibrillation (AF) following catheter ablation (CA) in individuals with T2DM qualitatively and quantitatively. METHODS: A comprehensive literature search was conducted in electronic databases. Studies meeting predefined criteria were included...
July 4, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38926266/effect-of-activated-charcoal-on-mavacamten-pharmacokinetics-in-healthy-participants
#5
JOURNAL ARTICLE
Samira Merali, Manting Chiang, Caroline Sychterz, Longfei Chao, Tara Simmons, Yiru Xu, Alice Zhao, Massimo Attanasio, Bindu Murthy, Vidya Perera
OBJECTIVE: To assess the effect of activated charcoal on the single-dose pharmacokinetics of mavacamten when administered 2 h or 6 h after mavacamten dosing. METHODS: In this open-label, randomized, parallel-group study, healthy adults were randomized into three groups to receive mavacamten 15 mg alone or mavacamten 15 mg plus activated charcoal 50 g administered either 2 h or 6 h after mavacamten dosing. Pharmacokinetic parameters were derived from plasma concentration-time data using noncompartmental methods...
June 26, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38913274/the-efficacy-of-tafolecimab-in-chinese-patients-with-hypercholesterolemia-a-systematic-review-and-meta-analysis
#6
JOURNAL ARTICLE
Eeshal Fatima, Zaheer Qureshi, Mikail Khanzada, Adnan Safi, Obaid Ur Rehman, Faryal Altaf
BACKGROUND: Cardiovascular disease was the leading cause of death worldwide in 2021, with atherosclerotic cardiovascular disease, encompassing hypercholesterolemia, being a major contributing factor. A range of lipid-lowering medications is used for the management of hyperlipidemia, but the use of statins is considered as standard therapy. Unfortunately, some patients do not respond to this therapy, necessitating novel therapeutic approaches. Tafolecimab is a novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody that inhibits the binding of PCSK9 with low-density lipoprotein receptors (LDLRs) and increases LDLR recycling, and thus it indirectly lowers circulating low-density lipoprotein cholesterol (LDL-C) levels by increasing LDL-C uptake...
June 24, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38909334/strategy-for-an-early-simultaneous-introduction-of-four-pillars-of-heart-failure-therapy-results-from-a-single-center-experience
#7
JOURNAL ARTICLE
Paolo Severino, Andrea D'Amato, Silvia Prosperi, Marco Valerio Mariani, Vincenzo Myftari, Aurora Labbro Francia, Claudia Cestiè, Elisa Tomarelli, Giovanna Manzi, Lucia Ilaria Birtolo, Stefanie Marek-Iannucci, Viviana Maestrini, Massimo Mancone, Roberto Badagliacca, Francesco Fedele, Carmine Dario Vizza
INTRODUCTION: The 2021 European Society of Cardiology (ESC) Guidelines recommend the use of four different classes of drugs for heart failure with reduced ejection fraction (HFrEF): beta blockers (BB), sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor/neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRAs). Moreover, the 2023 ESC updated Guidelines suggest an intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge, based on trials not using the four-pillars...
June 23, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38907865/ongoing-and-future-clinical-trials-of-pharmacotherapy-for-heart-failure
#8
REVIEW
Taha Mansoor, Subaina N Khalid, Muhammad Ibraiz Bilal, Sardar Hassan Ijaz, Marat Fudim, Stephen J Greene, Haider J Warraich, Vijay Nambi, Salim S Virani, Gregg C Fonarow, Dmitry Abramov, Abdul Mannan Khan Minhas
Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world.We used clinicaltrials.gov to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were "active, not recruiting", "recruiting", or looking for participants but "not yet recruiting"...
June 22, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38871947/impact-of-prolonged-dual-antiplatelet-therapy-after-bifurcation-percutaneous-coronary-intervention-in-patients-with-high-ischemic-risk
#9
JOURNAL ARTICLE
Dmitrii Khelimskii, Ivan Bessonov, Stanislav Sapozhnikov, Aram Badoyan, Aleksey Baranov, Mahmudov Mamurjon, Serezha Manukian, Ruslan Utegenov, Oleg Krestyaninov
BACKGROUND: The aim of this study was to evaluate the impact of prolonged dual antiplatelet therapy (DAPT) on clinical outcomes in patients undergoing percutaneous coronary interventions (PCI) for bifurcation coronary lesions. METHODS: A total of 1000 patients who underwent PCI for coronary bifurcation lesions and had clinical follow-up were divided into two groups based on the duration of DAPT: DAPT > 12 months and DAPT ≤ 12 months). Patients who experienced a myocardial infarction, required repeat PCI, or died within 1 year after the initial procedure were excluded...
June 13, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38856965/towards-the-fifth-pillar-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction-vericiguat-in-older-and-complex-patients
#10
REVIEW
Luigi Spadafora, Marco Bernardi, Gianmarco Sarto, Beatrice Simeone, Maurizio Forte, Luca D'Ambrosio, Matteo Betti, Alessandra D'Amico, Vittoria Cammisotto, Roberto Carnevale, Simona Bartimoccia, Pierre Sabouret, Giuseppe Biondi Zoccai, Giacomo Frati, Valentina Valenti, Sebastiano Sciarretta, Erica Rocco
Heart failure with reduced ejection fraction (HFrEF) represents an emerging epidemic, particularly affecting frail, older, and multimorbid patients. Current therapy for the management of HFrEF includes four different classes of disease-modifying drugs, commonly referred to as 'four pillars', which target the neurohormonal system that is overactivated in HF and contributes to its progression. These classes of drugs include β-blockers, inhibitors of the renin-angiotensin-aldosterone system, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter-2 (SGLT2) inhibitors...
June 10, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38850398/efficacy-and-safety-of-alprostadil-in-microcirculatory-disturbances-during-emergency-pci-a-meta-analysis-of-randomized-controlled-trials
#11
JOURNAL ARTICLE
Yue Chen, Mengdi Wang, Yali Yang, Min Zeng
OBJECTIVE: The clinical advantage of alprostadil [prostaglandin E1 (PGE1)] in the treatment of microcirculatory disturbances (defined as no-reflow or slow-flow) in acute percutaneous coronary intervention (PCI) is still disputed. The purpose of our study was to review the efficacy of PGE1 supplements in patients with acute myocardial infarction (AMI) who had urgent PCI. DESIGN: This study was a meta-analysis of randomized controlled trials. DATA SOURCES: PubMed, Embase, the Cochrane Library, Ovid, ProQuest, Scopus, the Chinese BioMedical Literature Database, China National Knowledge Internet, the China Science and Technology Journal Database, and the Wanfang Data Knowledge Service Platform were used as sources...
June 8, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38814501/correction-the-rationale-for-using-fixed%C3%A2-dose-combination-therapy-in-the-management-of-hypertension-in-colombia-a-narrative-review
#12
Dora Inés Molina de Salazar, Antonio Coca, Luis Alcocer, Daniel Piskorz
No abstract text is available yet for this article.
May 30, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38809412/efficacy-and-safety-of-interleukin-1-inhibitors-in-the-management-of-patients-with-recurrent-pericarditis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#13
Yong Wan, Shuai He, Shasha Wang, Tingli Xu, Minfang Qi, Pengcheng Gan
BACKGROUND: The efficacy and safety of interleukin-1 (IL-1) inhibitors in patients with recurrent pericarditis (RP) remain to be determined. OBJECTIVE: We aimed to conduct a meta-analysis to investigate the impact of IL-1 inhibitors on patients suffering from RP. METHODS: The Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases were systematically searched to identify articles investigating the effects of IL-1 inhibitors in patients with RP up until January 2024...
May 29, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38782884/benefits-and-risks-of-antihyperlipidemic-medication-in-adults-with-different-low-density-lipoprotein-cholesterol-based-on-the-number-needed-to-treat
#14
JOURNAL ARTICLE
Hong-Fei Wang, Yu-Cheng Mao, Su-Fen Qi, Xin-Yi Xu, Zi-Yan Zhang, Chang Geng, Kai Song, Qing-Bao Tian
PURPOSE: The objective of this investigation is to examine the benefits and potential risks of these drugs in individuals by varying baseline low-density lipoprotein cholesterol (LDL-C) values, utilizing the concept of the number needed to treat (NNT). METHODS: We extensively searched electronic databases, such as PubMed, EMBASE, Cochrane, and Web of Science, up to 6 August 2023. Baseline LDL-C values were stratified into four categories: < 100, 100-129, 130-159, and ≥ 160 mg/dL...
May 23, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38748390/beyond-weight-loss-evaluating-cardiovascular-advantages-of-glp-1-receptor-agonists
#15
LETTER
Teresa Vezza, Víctor M Víctor
No abstract text is available yet for this article.
May 15, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38734847/cardiovascular-benefits-of-glp-1-receptor-agonists-in-patients-living-with-obesity-or-overweight-a-meta-analysis-of-randomized-controlled-trials
#16
Gustavo de Oliveira Almeida, Thiago Faraco Nienkötter, Caroline Cristine Almeida Balieiro, Eric Pasqualotto, Júlia Braga Cintra, Henrique Champs Porfírio Carvalho, Ana Laura Soares Silva, Júlia Camargo Kabariti, Bárbara Silvestre Minucci, Edmundo Damiani Bertoli, Camila Mota Guida
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) have emerged as an effective therapeutic class for weight loss. However, the efficacy of these agents in reducing cardiovascular endpoints among patients living with obesity or overweight is unclear. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1 RAs versus placebo in patients with obesity or overweight. We searched PubMed, Cochrane, and Embase databases...
May 11, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38713309/evaluating-the-effectiveness-and-safety-of-evinacumab-in-treating-hypercholesterolemia-and-hypertriglyceridemia-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#17
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Muhammad Ashir Shafiq, Burhanuddin Sohail Rangwala, Vikash Virwani, Aashish Kumar, Syed Ali Arsal, Adarsh Raja, Sandesh Raja, Muhammad Saqlain Mustafa
BACKGROUND: Cardiovascular disease remains a significant global health concern, with high low-density lipoprotein cholesterol (LDL-C) levels contributing to an increased risk. Familial hypercholesterolemia (FH) further complicates its management, necessitating additional lipid-lowering therapies. Evinacumab, an angiopoietin-like protein 3 monoclonal antibody, has emerged as a potential treatment, particularly for patients with FH, by effectively reducing LDL-C and triglyceride levels...
May 7, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38691312/comparative-genitourinary-safety-of-in-class-sodium-glucose-cotransporter-2-inhibitors-among-patients-with-heart-failure-with-preserved-ejection-fraction-a-cohort-study
#18
JOURNAL ARTICLE
Munaza Riaz, Jingchuan Guo, Steven M Smith, Eric A Dietrich, David E Winchester, Haesuk Park
PURPOSE: The American Heart Association recommended sodium-glucose cotransporter-2 inhibitors (SGLT2i) for the management of heart failure with preserved ejection fraction (HFpEF). However, little is known about their real-world in-class comparative safety in patients with HFpEF. We aimed to assess the comparative safety of SGLT2i in the risk of urinary tract infection (UTI) or genital infection separately or as a composite outcome among patients with HFpEF. METHODS: This cohort study using MarketScan® Commercial and Medicare supplemental databases (2012-2020) included patients aged ≥ 18 years with a diagnosis of HFpEF who initiated SGLT2i therapy...
April 30, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38683263/differential-use-of-glycoprotein-iib-iiia-inhibitors-with-bivalirudin-in-patients-with-stemi-undergoing-pci-a-systematic-review-and-meta-analysis
#19
JOURNAL ARTICLE
Hasan Mushahid, Syeda Ayesha Shah, Syed Husain Farhan, Muhammad Hamza Shuja, Kyle Balasingam, Asad Ali Siddiqui, Ishaque Hameed, Kamran Akram, Shayan Mushahid, Muhammad Shariq Usman
AIM: The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. METHODS: Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion...
May 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38619802/cost-utility-analysis-of-vericiguat-in-heart-failure-with-reduced-ejection-fraction-after-worsening-heart-failure-events-in-china
#20
JOURNAL ARTICLE
Penglei Chen, Yixiang Wang, Xin Liu, Jiaqi Yu, Xuwei Zheng
OBJECTIVE: Vericiguat is a new medication to demonstrate clinical efficacy in heart failure with reduced ejection fraction (HFrEF) after worsening heart failure (WHF) events, but its cost-utility was unknown. We aimed to assess the cost-utility of combining the application of vericiguat with standard treatment in HFrEF patients who had WHF events. METHODS: A multistate Markov model was implemented to mimic the economic results of HFrEF patients who had WHF events in China after receiving vericiguat or placebo...
April 15, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
journal
journal
35888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.